0001193125-26-095014
SEC filingPMV Pharmaceuticals, Inc. reported a net loss of $77.7 million for FY 2025, an increase from a net loss of $58.7 million in FY 2024. The company generated no revenue, consistent with prior periods, as it remains a clinical-stage precision oncology company focused on developing p53-targeted therapies. Total operating expenses were $86.2 million, driven primarily by a $69.9 million investment in research and development, which increased by $11.4 million year-over-year due to advancing its lead candidate, rezatapopt, through Phase 2 clinical trials. This was partially offset by a $10.6 million decrease in general and administrative expenses. The company ended the year with $112.9 million in cash, cash equivalents, and marketable securities, which it estimates will fund operations until the end of Q2 2027. A key forward-looking event is the planned submission of a New Drug Application for rezatapopt in Q1 2027.
PMV Pharmaceuticals reported a net loss of $77.7 million for the fiscal year ended December 31, 2025, compared to a net loss of $58.7 million in FY 2024, representing a significant increase in losses. The company generated no revenue in either period. The increased loss was driven by higher operating expenses, which totaled $86.2 million in FY 2025, up from $85.4 million in FY 2024. A major component was research and development expense, which rose by $11.4 million to $69.9 million, primarily due to increased clinical trial activities for the lead product candidate, rezatapopt. This was partially offset by a $10.6 million decrease in general and administrative expenses, largely due to costs related to the termination of a prior headquarters lease.
The company has not generated any revenue from product sales or other sources to date. The document explicitly states, "To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future." Future revenue generation is contingent upon the successful development, regulatory approval, and commercialization of one or more product candidates, with the lead candidate, rezatapopt, being the primary focus. No segment or geographic revenue breakdown is provided or applicable.
As a pre-revenue company, traditional margin metrics like gross margin are not applicable. The company's operating loss was $86.2 million for FY 2025, slightly higher than the $85.4 million operating loss in FY 2024. The cost structure is dominated by research and development, which constituted approximately 81% of total operating expenses in FY 2025. The year-over-year increase in R&D costs reflects the company's advancement of rezatapopt into the pivotal Phase 2 portion of its clinical trial. The decrease in G&A expenses provided a partial offset, improving the overall operating loss position marginally compared to the prior year.
Net cash used in operating activities was $73.6 million for FY 2025, an increase from $51.3 million used in FY 2024, aligning with the higher net loss. The company's investing activities provided $70.2 million in cash, primarily from maturities of marketable securities exceeding purchases. Financing activities provided a nominal $0.5 million from stock option exercises. The company ended the period with $112.9 million in cash, cash equivalents, and marketable securities, down from $183.3 million at the end of FY 2024. Total assets were $116.6 million, with current assets of $115.2 million significantly exceeding current liabilities of $11.4 million, indicating a strong short-term liquidity position. The accumulated deficit stood at $446.5 million.
Management expects operating expenses to increase significantly as product candidates advance through development and toward potential commercialization. The company plans to submit a New Drug Application (NDA) for rezatapopt for the treatment of TP53 Y220C-mutant ovarian cancer in the first quarter of 2027. Based on current plans, management estimates that existing cash, cash equivalents, and marketable securities will be sufficient to fund planned operations until the end of the second quarter of 2027. The company acknowledges that this estimate is based on assumptions that may prove wrong and that it will need to secure additional funding through equity or debt financing, or collaborations, to continue operations thereafter. Key risks include the uncertainty of clinical trial outcomes, regulatory approvals, and the ability to raise necessary capital.